goetzpartners advised Pharmaron
goetzpartners advised Pharmaron on its acquisition of Aesica Pharmaceuticals Limited from Recipharm
Pharmaron (Stock Code: 300759.SZ/3759.HK), a premier research and development service provider for the life science industry, announced today that it has acquired Aesica Pharmaceuticals Limited (“The Cramlington Site”) from Recipharm group.
The Cramlington Site in Newcastle, United Kingdom, has an established history of cGMP manufacturing services for an array of Active Pharmaceutical Ingredients (API), ranging from pilot scale to commercial metric ton scale. The Cramlington Site has more than 100 cubic meter reactor commercial capacity and has been inspected and approved by the MHRA, FDA and other regulatory authorities.
This acquisition expands Pharmaron's world-class chemistry and manufacturing services, and further strengthens Pharmaron’s global service network to provide customized solutions to meet its partners’ geographic and strategic needs.
goetzpartners acted as exclusive M&A advisor to Pharmaron in the transaction.
Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 15,000 employees, and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.